These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
492 related articles for article (PubMed ID: 19712003)
1. Disease biomarkers in multiple sclerosis: potential for use in therapeutic decision making. Harris VK; Sadiq SA Mol Diagn Ther; 2009; 13(4):225-44. PubMed ID: 19712003 [TBL] [Abstract][Full Text] [Related]
2. Glial and neuroaxonal biomarkers in a multiple sclerosis (MS) cohort. Kalatha T; Hatzifilippou E; Arnaoutoglou M; Balogiannis S; Koutsouraki E Hell J Nucl Med; 2019; 22 Suppl 2():113-121. PubMed ID: 31802051 [TBL] [Abstract][Full Text] [Related]
3. Biomarkers of therapeutic response in multiple sclerosis: current status. Harris VK; Sadiq SA Mol Diagn Ther; 2014 Dec; 18(6):605-17. PubMed ID: 25164543 [TBL] [Abstract][Full Text] [Related]
5. Biomarkers of inflammation and axonal degeneration/damage in patients with newly diagnosed multiple sclerosis: contributions of the soluble CD163 CSF/serum ratio to a biomarker panel. Stilund M; Gjelstrup MC; Petersen T; Møller HJ; Rasmussen PV; Christensen T PLoS One; 2015; 10(4):e0119681. PubMed ID: 25860354 [TBL] [Abstract][Full Text] [Related]
6. Blood Biomarkers as Outcome Measures in Inflammatory Neurologic Diseases. El Ayoubi NK; Khoury SJ Neurotherapeutics; 2017 Jan; 14(1):135-147. PubMed ID: 27757816 [TBL] [Abstract][Full Text] [Related]
7. Can CSF biomarkers predict future MS disease activity and severity? Magliozzi R; Cross AH Mult Scler; 2020 Apr; 26(5):582-590. PubMed ID: 31965889 [TBL] [Abstract][Full Text] [Related]
10. Biological markers for multiple sclerosis. Lutterotti A; Berger T; Reindl M Curr Med Chem; 2007; 14(18):1956-65. PubMed ID: 17691938 [TBL] [Abstract][Full Text] [Related]
11. The role of magnetic resonance techniques in understanding and managing multiple sclerosis. Miller DH; Grossman RI; Reingold SC; McFarland HF Brain; 1998 Jan; 121 ( Pt 1)():3-24. PubMed ID: 9549485 [TBL] [Abstract][Full Text] [Related]
12. Evaluating biomarkers of neuronal degeneration and neuroinflammation in CSF of patients with multiple sclerosis-osteopontin as a potential marker of clinical severity. Szalardy L; Zadori D; Simu M; Bencsik K; Vecsei L; Klivenyi P J Neurol Sci; 2013 Aug; 331(1-2):38-42. PubMed ID: 23706476 [TBL] [Abstract][Full Text] [Related]
13. [Axonal Regeneration-related Molecules as Biomarkers for Multiple Sclerosis]. Takahashi K; Tanaka F; Takei K Brain Nerve; 2016 Jan; 68(1):82-9. PubMed ID: 26764302 [TBL] [Abstract][Full Text] [Related]
14. Insight into Early Diagnosis of Multiple Sclerosis by Targeting Prognostic Biomarkers. Puranik N; Yadav D; Song M Curr Pharm Des; 2023; 29(32):2534-2544. PubMed ID: 37921136 [TBL] [Abstract][Full Text] [Related]
15. Cerebrospinal fluid fetuin-A is a biomarker of active multiple sclerosis. Harris VK; Donelan N; Yan QJ; Clark K; Touray A; Rammal M; Sadiq SA Mult Scler; 2013 Oct; 19(11):1462-72. PubMed ID: 23439582 [TBL] [Abstract][Full Text] [Related]
16. Cholesterol and markers of cholesterol turnover in multiple sclerosis: relationship with disease outcomes. Zhornitsky S; McKay KA; Metz LM; Teunissen CE; Rangachari M Mult Scler Relat Disord; 2016 Jan; 5():53-65. PubMed ID: 26856944 [TBL] [Abstract][Full Text] [Related]
17. The diagnosis of multiple sclerosis and the various related demyelinating syndromes: a critical review. Karussis D J Autoimmun; 2014; 48-49():134-42. PubMed ID: 24524923 [TBL] [Abstract][Full Text] [Related]